Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00597727 · ClinicalTrials.gov registry record · Phase 2

A Study of Sublingual Immunotherapy in Peanut-allergic Children

A Phase 2 study of Food Hypersensitivity, sponsored by University of North Carolina, Chapel Hill.

Completed
Registry status
Phase 2
Development phase
60
Enrollment target
1
Study location

NCT00597727 is a Phase 2 study of Food Hypersensitivity that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 60 participants, below the 4,651-participant average among 5 other Food Hypersensitivity trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00597727, a Phase 2 study of Food Hypersensitivity, has completed, sponsored by University of North Carolina, Chapel Hill.

COMPLETED
Registry status
Phase 2
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

The specific aim of this study is to determine if peanut allergen-specific SLIT will cause clinical desensitization and tolerance to develop in peanut-allergic young children.

Conditions Studied

Interventions

  • DRUG Peanut SLIT
  • DRUG Placebo SLIT

Study Locations (1)

North Carolina

  • University of North Carolina - Chapel Hill

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2008-01
Est. Completion 2016-03
Phase Phase 2

What the Registry Record Tells You About NCT00597727

The ClinicalTrials.gov registry entry for NCT00597727 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,651-participant average among 5 other Food Hypersensitivity trials with a reported enrollment target (99% lower). The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Food Hypersensitivity appearing as the primary indexed condition, and to 2 interventions - of which Peanut SLIT is the first listed.

NCT00597727 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT00597727 about?

NCT00597727 is a clinical study titled "A Study of Sublingual Immunotherapy in Peanut-allergic Children". The specific aim of this study is to determine if peanut allergen-specific SLIT will cause clinical desensitization and tolerance to develop in peanut-allergic young children.

What is the current status of trial NCT00597727?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2008-01. Estimated completion is 2016-03.

What conditions does trial NCT00597727 study?

This clinical trial studies the following conditions: Food Hypersensitivity.

What interventions are being tested in trial NCT00597727?

The interventions under investigation include: Peanut SLIT (DRUG), Placebo SLIT (DRUG).

Who is sponsoring clinical trial NCT00597727?

This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00597727 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Food Hypersensitivity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.